A multi-center, randomized phase III study of adjuvant Oncophage [vitespen] versus observation in subjects with high risk of recurrence after surgical treatment for renal cell carcinoma.
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Vitespen (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms INSPIRE
- Sponsors Agenus
- 09 Jun 2009 Status changed from completed to active, no longer recruiting as patients will be followed up in the INSPIRE registry.
- 31 May 2009 Interim survival data from the INSPIRE registry presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009).
- 15 Apr 2009 New source identified and integrated (M.D. Anderson Cancer Center record).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History